Highly stable mutant reverse transcriptase
By modifying cysteine residues in reverse transcriptases with nonpolar amino acids, the stability and thermostability of these enzymes are enhanced, enabling stable and efficient cDNA synthesis.
Patent Information
- Application Number
- JP2021536980
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-07-26
- Filing Date
- 2020-07-21
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2040-07-21
AI Technical Summary
Existing reverse transcriptases suffer from low thermostability and storage stability, leading to enzyme inactivation at high temperatures and during storage, which complicates their handling and usage in applications like cDNA synthesis.
Modifying cysteine residues at specific positions in the reverse transcriptase amino acid sequence, such as positions 90, 157, 236, 262, 310, 409, 495, and 635, with nonpolar amino acids like alanine, glycine, or isoleucine, to enhance thermostability and storage stability.
The modified reverse transcriptases exhibit improved residual activity rates of 30% or more after 35 days at 25°C and higher thermostability, allowing efficient reverse transcription reactions even at elevated temperatures.
Smart Images

Figure 0007593316000005 
Figure 0007593316000006 
Figure 0007593316000001
Abstract
Description
[Technical field]
[0001] The present invention relates to a mutant reverse transcriptase. More specifically, the present invention relates to a mutant reverse transcriptase having excellent storage stability over time and thermal stability, as well as a reverse transcription method using the mutant reverse transcriptase, a polynucleotide encoding the mutant reverse transcriptase, a kit containing the mutant reverse transcriptase, and the like. [Background technology]
[0002] Reverse transcriptase generally has an activity of synthesizing cDNA using RNA as a template (hereinafter referred to as "RNA-dependent DNA polymerase activity") and an activity of degrading the RNA strand in an RNA:DNA hybrid (hereinafter referred to as "RNase H activity"). Reverse transcriptase is used, for example, in the analysis of the base sequence of mRNA that directly reflects the amino acid sequence of a protein expressed in a living body, the construction of a cDNA library, RT-PCR, and the like. As reverse transcriptases used for such purposes, Moloney murine leukemia virus reverse transcriptase (MMLV) or avian myeloblastosis virus reverse transcriptase (AMV) are known.
[0003] In addition, when mRNA has a base sequence that easily forms a secondary structure, the synthesis of cDNA by reverse transcriptase is hindered by the secondary structure, so it is desirable to synthesize cDNA while suppressing the formation of the secondary structure by increasing the reaction temperature. However, the Moloney murine leukemia virus reverse transcriptase and the avian myeloblastosis virus reverse transcriptase often have low thermal stability, and may be inactivated at high temperatures that suppress the formation of secondary structures in RNA. In recent years, various mutant reverse transcriptases have been developed that have higher thermal stability than wild-type reverse transcriptases and have improved reactivity even at 42 to 60°C, which is usually poorly stable, by introducing multiple amino acid mutations into reverse transcriptase (Patent Documents 1 and 2, Non-Patent Document 1).
[0004] In addition, reverse transcriptase is known to have low storage stability, and may be gradually inactivated and lose its enzymatic activity not only at high temperatures where the formation of secondary structures in RNA is suppressed, but also during storage under relatively mild conditions such as 4°C and 25°C. Therefore, strict temperature control during storage and transportation, as well as expiration date management, are required.
[0005] For the reasons mentioned above, there has been a need for the development of a novel and more useful reverse transcriptase having improved thermal stability and / or improved stability over time during storage compared to conventional methods. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] JP 2000-139457 A [Patent Document 2] Patent No. 6180002 [Non-patent literature]
[0007] [Non-Patent Document 1] Journal of Biotechnology, Vol. 150, Issue 3, Pages 299-306, (Published in 2010) Summary of the Invention [Problem to be solved by the invention]
[0008] The present invention has been made in consideration of the above-mentioned conventional techniques, and an objective of the present invention is to provide a novel and more useful mutant reverse transcriptase having improved storage stability and / or thermal stability over time. [Means for solving the problem]
[0009] In view of the above-mentioned problems, the inventors conducted intensive research and discovered that by modifying cysteine residues at specific sites in reverse transcriptase, a reverse transcriptase having improved storage stability and / or thermal stability over time can be obtained, thereby arriving at the present invention.
[0010] That is, the representative present invention has the following configuration. [Item 1] A mutant reverse transcriptase having an amino acid sequence that has 90% or more identity to the amino acid sequence set forth in SEQ ID NO:1, in which a cysteine residue is modified at at least one position selected from the group consisting of positions 90, 157, 236, 262, 310, 409, 495, and 635. [Item 2] A mutant reverse transcriptase according to Item 1, comprising an amino acid sequence having one or more deletions, substitutions and / or additions of amino acid residues in the amino acid sequence set forth in SEQ ID NO:1, in which cysteine residues are modified at at least one position selected from the group consisting of positions 90, 157, 236, 262, 310, 409, 495 and 635. [Item 3] The mutant reverse transcriptase according to Item 1 or 2, wherein the modification of the cysteine residue is deletion of the cysteine residue and / or substitution with another amino acid residue. [Item 4] The mutant reverse transcriptase described in any one of Items 1 to 3, wherein the modification of the cysteine residue is a substitution with at least one nonpolar amino acid residue selected from the group consisting of alanine, glycine, valine, leucine, and isoleucine. [Item 5] The mutant reverse transcriptase according to any one of Items 1 to 4, wherein the modification of the cysteine residue is a substitution with an alanine residue. [Item 6] A mutant reverse transcriptase according to any one of Items 1 to 5, characterized in that in an amino acid sequence having 90% or more identity to the amino acid sequence set forth in SEQ ID NO:1, at least a cysteine residue at a position corresponding to position 310 has been modified. [Item 7] A mutant reverse transcriptase described in any of Items 1 to 6, wherein the modification of the cysteine residue at the position corresponding to position 310 is a substitution with a non-polar amino acid residue selected from the group consisting of alanine, glycine, valine, leucine, and isoleucine. [Item 8] The mutant reverse transcriptase according to any one of Items 1 to 7, wherein the modification of the cysteine residue at the position corresponding to position 310 is a substitution with an alanine residue. [Item 9] A mutant reverse transcriptase according to any one of Items 1 to 8, which lacks RNase activity. [Item 10] A mutant reverse transcriptase that exhibits a residual activity rate of 30% or more when stored at 25°C for 35 days. [Item 11] A mutant reverse transcriptase that exhibits a residual activity rate of 50% or more when stored at 25°C for 35 days. [Item 12] A polynucleotide encoding the reverse transcriptase according to any one of Items 1 to 8. [Item 13] A vector comprising the polynucleotide described in Item 12. [Item 14] A cell transformed with the vector described in Item 13. [Item 15] A reagent comprising at least one selected from the group consisting of the mutant reverse transcriptase described in any one of Items 1 to 11, the polynucleotide described in Item 12, the vector described in Item 13, and the cell described in Item 14. [Item 16] A method for producing the mutant reverse transcriptase according to any one of items 1 to 11, using at least one selected from the group consisting of the polynucleotide according to item 12, the vector according to item 13, the cell according to item 14, and the reagent according to item 15. [Item 17] A method for reverse transcription, comprising synthesizing cDNA from an RNA template using the mutant reverse transcriptase according to any one of Items 1 to 11. [Item 18] A kit comprising the mutant reverse transcriptase described in any one of Items 1 to 11. [Item 19] The kit according to Item 18, which is used to synthesize cDNA using RNA as a template. Effect of the Invention
[0011] The present invention provides a novel and useful mutant reverse transcriptase having improved storage stability over time and / or thermal stability. The mutant reverse transcriptase of the present invention has excellent storage stability over time, which makes it easier to handle during storage, transportation, etc., and can be used as a highly convenient reagent. In addition, the mutant reverse transcriptase of the present invention has excellent thermal stability, which allows efficient reverse transcription reaction, for example, in a nucleic acid synthesis method including a step of increasing the reaction temperature. [Brief description of the drawings]
[0012] [Figure 1] FIG. 1 shows the results of a stability test of wild-type reverse transcriptase (WT) in Example 4. [Diagram 2] FIG. 1 shows the results of a stability test of the mutant reverse transcriptase (C310A) of the present invention in Example 4. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0013] The present invention will be described in detail below, but the present invention is not limited thereto.
[0014] The mutant reverse transcriptase of the present invention is characterized in that a cysteine residue at a specific position in a wild-type reverse transcriptase is modified. The present invention is based on the new finding that modification of a cysteine residue improves storage stability over time and makes it possible to obtain a reverse transcriptase with excellent thermal stability. Cysteine has a thiol group, and generally contributes to maintaining the tertiary structure of a protein through the formation of a disulfide bond or the like. The present invention aims to change the performance of a reverse transcriptase and improve its thermal stability and / or storage stability by modifying such a cysteine residue (e.g., deleting and / or substituting it with another amino acid).
[0015] Therefore, in the present invention, it is sufficient to modify a cysteine residue at a predetermined position in a wild-type reverse transcriptase, and the manner of modification of the cysteine residue is not limited as long as the effects of the present invention are achieved. As an example, the modification of the cysteine residue may be deletion of the cysteine residue and / or substitution with another amino acid. From the viewpoint of more reliably achieving a high stabilizing effect, substitution with another amino acid residue is preferable, and in particular substitution with a non-polar amino acid residue is preferable. The mutant reverse transcriptase of the present invention as described above is characterized by having reverse transcription activity and having improved thermal stability and / or storage stability compared to the reverse transcriptase before modification.
[0016] In the present invention, the term "wild-type reverse transcriptase" (hereinafter also referred to as "WT") refers to a reverse transcriptase in which no mutation has been artificially introduced. Examples of the wild-type reverse transcriptase include a reverse transcriptase consisting of the amino acid sequence set forth in SEQ ID NO: 1. Here, the "amino acid sequence set forth in SEQ ID NO: 1" refers to the amino acid sequence set forth in SEQ ID NO: 1 in the sequence listing (Moloney murine leukemia virus reverse transcriptase). Furthermore, "Moloney murine leukemia virus reverse transcriptase" may also be expressed as "MMLV reverse transcriptase". The present invention may be a mutant reverse transcriptase derived from the amino acid sequence of Moloney murine leukemia virus reverse transcriptase, but may also be a mutant reverse transcriptase derived from a protein (e.g., ortholog, homolog, etc.) consisting of an amino acid sequence that is in a predetermined relationship with the amino acid sequence set forth in SEQ ID NO: 1 and has high homology from the viewpoint of the identity of the amino acid sequence, etc. From the viewpoint of more reliably obtaining a high stability improvement effect, the mutant reverse transcriptase derived from the amino acid sequence of Moloney murine leukemia virus reverse transcriptase is preferable.
[0017] In one embodiment, the mutant reverse transcriptase of the present invention is characterized in that it is a mutant reverse transcriptase containing a modification in a cysteine residue at at least one position selected from the group consisting of positions 90, 157, 236, 262, 310, 409, 495, and 635 in the amino acid sequence shown in SEQ ID NO: 1. The amino acid sequence before modification is not limited to being completely identical to SEQ ID NO: 1, and is not particularly limited as long as the reverse transcription activity is not lost. For example, it is preferable to have an amino acid sequence that has an identity of 90% or more, preferably 95% or more, more preferably 96% or more, even more preferably 97% or more, even more preferably 98% or more, and especially 99% or more with the amino acid sequence shown in SEQ ID NO: 1. Here, the identity of the amino acid sequence can be evaluated by any means known in the art. For example, the amino acid sequence identity can be calculated using a commercially available analysis tool or an analysis tool available via an electric communication line (Internet). For example, the identity of the amino acid sequence can be calculated using the default (initial setting) parameters in the homology algorithm BLAST (Basic local alignment search tool) of the National Center for Biotechnology Information (NCBI) http: / / www.ncbi.nlm.nih.gov / BLAST / . Furthermore, the amino acid sequence before modification may be an amino acid sequence in which one or several amino acids are deleted, substituted, and / or added in the amino acid sequence set forth in SEQ ID NO: 1. Here, "one or several" is not particularly limited as long as the reverse transcription activity is not lost, and is, for example, 1 to 20, preferably 1 to 10, more preferably 1 to 5, and even more preferably 1 to 3. The amino acid sequence before modification as described above may be, for example, one artificially produced by a genetic engineering technique, or may be the amino acid sequence of a naturally derived protein.
[0018] In this specification, simplified symbols using alphabetical notation may be used for the base sequence, amino acid sequence, and each of their constituent factors, but all of them follow the conventions in the fields of molecular biology and genetic engineering. In this specification, in order to simply indicate a mutation in an amino acid sequence, for example, "C90A" is used. "C90A" indicates that the 90th cysteine has been replaced with alanine, that is, it indicates the type of amino acid residue before the replacement, its location, and the type of amino acid residue after the replacement. In addition, unless otherwise specified, the sequence number corresponds to the sequence number listed in the sequence table. In addition, in the case of multiple mutants, the above notations are connected with " / ". In addition, in this specification, a site corresponding to a certain position (order) on SEQ ID NO: 1 in an amino acid sequence that is not completely identical to the amino acid sequence shown in SEQ ID NO: 1 refers to a position that corresponds to the corresponding position on SEQ ID NO: 1 when the primary structures of the sequences are compared (aligned).
[0019] Furthermore, in this specification, "mutant" or "modified" in the case of "mutant reverse transcriptase" or "modified reverse transcriptase" are used interchangeably and mean that the reverse transcriptase has an amino acid sequence different from that of conventionally known reverse transcriptases, and do not distinguish between artificial mutations and mutations occurring in nature. Thus, the mutant reverse transcriptase of the present invention refers to a reverse transcriptase having an amino acid sequence different from that of SEQ ID NO: 1, in which one or more amino acids have been modified, regardless of whether the mutant reverse transcriptase is a reverse transcriptase obtained by artificial mutation or a reverse transcriptase obtained by mutation in nature.
[0020] In a particular preferred embodiment, the reverse transcriptase of the present invention is one in which a cysteine residue at at least one position selected from the group consisting of positions 90, 157, 236, 262, 310, 409, 495, and 635 in the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having a predetermined relationship with the amino acid sequence of SEQ ID NO: 1 in terms of amino acid sequence identity, etc., has been modified. Thus, the mutant reverse transcriptase of the present invention may have cysteine residues at two or more positions in the amino acid sequence, or cysteine residues at three or more, four or more, five or more, six or more, seven or more positions, or cysteine residues at all of the eight positions specified above, as long as the effect of the present invention is achieved. As shown in the results of the Examples described later, it has been shown that a particularly high stabilizing effect is achieved by modifying the cysteine residue at the position corresponding to position 310 in SEQ ID NO: 1. Thus, in certain preferred embodiments, at least the cysteine residue at the position corresponding to position 310 in the amino acid sequence as set forth above may be modified.
[0021] In a specific preferred embodiment, the mutant reverse transcriptase of the present invention has a cysteine residue at at least one position selected from the group consisting of 90, 157, 236, 262, 310, 409, 495, and 635 in the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence that has a specific relationship to the amino acid sequence set forth in SEQ ID NO: 1 in terms of amino acid sequence identity, etc., substituted with a nonpolar amino acid. Preferably, the cysteine residue at at least one position selected from the group consisting of 90th, 157th, 236th, 262nd, 310th, 409th, 495th, and 635th positions is replaced with glycine, alanine, isoleucine, leucine, valine, phenylalanine, proline, methionine, or tryptophan; more preferably, glycine, alanine, isoleucine, leucine, valine, phenylalanine, or proline; even more preferably, glycine, alanine, isoleucine, leucine, or valine; even more preferably, glycine, alanine, or isoleucine, and among these, alanine or isoleucine is preferred. Glycine, alanine, isoleucine, leucine, and valine are non-polar amino acids, and are known to have an isoelectric point of about 6.0, and are expected to exert the same effects as amino acids that can exhibit common properties.
[0022] The mutant reverse transcriptase of the present invention can be obtained, for example, by producing a protein in which a cysteine residue at at least one position selected from the group consisting of positions 90, 157, 236, 262, 310, 409, 495, and 635 in the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having a predetermined relationship with the amino acid sequence described in SEQ ID NO: 1 in terms of amino acid sequence identity, etc., is modified. The method of introducing an amino acid modification in an amino acid sequence can be appropriately performed by a person skilled in the art using any method known in the art. For example, a mutation can be introduced into a gene encoding a wild-type reverse transcriptase, and a new mutant reverse transcriptase protein in which an amino acid modification is introduced at a predetermined position can be produced by protein engineering techniques. As one embodiment of the method of introducing an amino acid modification, a site-directed mutagenesis method based on the Inverse PCR method can be used. For example, the KOD-Plus-Mutagenesis Kit (manufactured by Toyobo) is a kit that can obtain a transformant carrying a plasmid into which a target gene has been inserted by (1) denaturing a plasmid into which a target gene has been inserted, annealing a mutation primer to the plasmid, and then performing an extension reaction using KOD DNA polymerase; (2) repeating the cycle of (1) 15 times; (3) selectively cleaving only the template plasmid using the restriction enzyme DpnI; (4) phosphorylating the newly synthesized gene and ligating it to cyclize it; and (5) transforming the cyclized gene into Escherichia coli, thereby obtaining a transformant carrying a plasmid into which a target mutation has been introduced. The kit can be suitably used for producing the mutant reverse transcriptase of the present invention.
[0023] In a particular embodiment, the mutant reverse transcriptase of the present invention may lack RNase activity. An example of a mutant reverse transcriptase lacking RNase activity is one in which the aspartic acid at the position corresponding to position 524 is replaced with alanine, but is not limited thereto. The RNase activity generally possessed by wild-type reverse transcriptase may degrade RNA, which is a template for reverse transcription reaction, and may be problematic, particularly when synthesizing cDNA using a long-chain RNA (e.g., full-length RNA) as a template. A mutant reverse transcriptase modified to lack RNase activity is preferable because it can suppress the degradation of the RNA chain template during the reverse transcription reaction using a long-chain RNA as a template.
[0024] As shown in the results of the test examples described later, the present invention can provide a mutant reverse transcriptase having improved storage stability and / or thermal stability. In a preferred embodiment, the mutant reverse transcriptase provided by the present invention is a mutant reverse transcriptase having excellent properties in both storage stability and thermal stability.
[0025] Specifically, the mutant reverse transcriptase having excellent storage stability over time provided by the present invention may be, for example, a mutant reverse transcriptase exhibiting a residual activity rate of 20% or more when stored at 25° C. for 35 days. The mutant reverse transcriptase may preferably exhibit a residual activity rate of 30% or more, more preferably exhibit a residual activity rate of 40% or more, and even more preferably exhibit a residual activity rate of 50% or more when stored at 25° C. for 25 days. Furthermore, the mutant reverse transcriptase having excellent storage stability over time of the present invention may be, for example, a mutant reverse transcriptase exhibiting a residual activity rate of 20% or more, preferably exhibiting a residual activity rate of 30% or more, more preferably exhibiting a residual activity rate of 40% or more, preferably exhibiting a residual activity rate of 45% or more, more preferably exhibiting a residual activity rate of 50% or more, and even more preferably exhibiting a residual activity rate of 60% or more when stored at 25° C. for 10 days. A mutant reverse transcriptase that exhibits such a high remaining activity rate after long-term storage can be appropriately obtained by a person skilled in the art, for example, by modifying amino acids in the amino acid sequence set forth in SEQ ID NO: 1 or an amino acid sequence that has a specific relationship to the amino acid sequence set forth in SEQ ID NO: 1 in terms of amino acid sequence identity, etc., and evaluating the obtained mutant reverse transcriptase by measuring the remaining activity rate as described below.
[0026] In a specific embodiment, the mutant reverse transcriptase having excellent storage stability over time provided by the present invention may be, for example, a mutant reverse transcriptase that exhibits a higher residual activity rate than that of the wild-type reverse transcriptase when stored at 25° C. for 10 days, 25 days, or 35 days. Specifically, for example, the mutant reverse transcriptase exhibits a higher residual activity rate than that of the wild-type reverse transcriptase when stored at 25° C. for 10 days. Furthermore, for example, the mutant reverse transcriptase exhibits a higher residual activity rate than that of the wild-type reverse transcriptase when stored at 25° C. for 25 days. The mutant reverse transcriptase exhibits a higher residual activity rate than that of the wild-type reverse transcriptase by about 1.1 times or more, preferably about 1.5 times or more, more preferably about 2 times or more, and particularly preferably 4 times or more. Furthermore, for example, the mutant reverse transcriptase may exhibit a residual activity rate that is at least about 1.1 times, preferably at least about 1.5 times, more preferably at least about 2 times, and particularly preferably at least about 4 times, higher than that of the wild-type reverse transcriptase when stored for 35 days at 25° C. A mutant reverse transcriptase exhibiting such a high residual activity rate after long-term storage at 25° C. can be appropriately obtained by those skilled in the art by evaluating both the wild-type reverse transcriptase and the mutant reverse transcriptase in which an amino acid residue has been modified by measuring the residual activity rate as described below and comparing the value of the residual activity rate with that of the wild-type reverse transcriptase.
[0027] In a further embodiment, the mutant reverse transcriptase having excellent thermostability provided by the present invention may be, for example, a mutant reverse transcriptase that exhibits a residual activity rate of 70% or more when heat-treated at 45° C. for 5 minutes. Furthermore, the mutant reverse transcriptase having excellent thermostability of the present invention may be, for example, a mutant reverse transcriptase that exhibits a residual activity rate of 65% or more when heat-treated at 45° C. for 10 minutes. Furthermore, the mutant reverse transcriptase having excellent thermostability of the present invention may be, for example, a mutant reverse transcriptase that exhibits a residual activity rate of 65% or more, preferably a residual activity rate of 68% or more, when heat-treated at 50° C. for 5 minutes. In addition, the mutant reverse transcriptase having excellent thermostability of the present invention may be, for example, a mutant reverse transcriptase that exhibits a residual activity rate of 20% or more, preferably a residual activity rate of 25% or more, when heat-treated at 55° C. for 5 minutes. A mutant reverse transcriptase that exhibits such a high residual activity rate after heat treatment can be appropriately obtained by a person skilled in the art, for example, by modifying amino acids in the amino acid sequence set forth in SEQ ID NO: 1 or an amino acid sequence that has a specific relationship to the amino acid sequence set forth in SEQ ID NO: 1 in terms of amino acid sequence identity, etc., and evaluating the obtained mutant reverse transcriptase by measuring the residual activity rate as described below.
[0028] In a specific embodiment, the mutant reverse transcriptase with excellent thermostability provided by the present invention may be a mutant reverse transcriptase that exhibits a higher residual activity rate than that of the wild-type reverse transcriptase when heat-treated at 45° C. for 5 minutes, at 50° C. for 5 minutes, or at 55° C. for 5 minutes. Specifically, the mutant reverse transcriptase may exhibit a higher residual activity rate than that of the wild-type reverse transcriptase when heat-treated at 45° C. for 5 minutes, which is about 1.1 times or more, preferably about 1.2 times or more, more preferably about 1.3 times or more, and even more preferably about 1.4 times or more. Furthermore, the mutant reverse transcriptase may exhibit a higher residual activity rate than that of the wild-type reverse transcriptase when heat-treated at 50° C. for 5 minutes, which is about 1.1 times or more, preferably about 1.2 times or more. Furthermore, for example, the mutant reverse transcriptase may exhibit a residual activity rate that is at least about 1.1 times, preferably at least about 1.2 times, more preferably at least about 1.4 times, and particularly preferably at least about 1.6 times, higher than that of the wild-type reverse transcriptase when heat-treated for 5 minutes at 55° C. A mutant reverse transcriptase exhibiting such a high residual activity rate after heat treatment can be appropriately obtained by those skilled in the art by evaluating both the wild-type reverse transcriptase and the mutant reverse transcriptase in which amino acid residues have been modified by measuring the residual activity rate as described below, and comparing the value of the residual activity rate with that of the wild-type reverse transcriptase.
[0029] [Method for measuring reverse transcription activity] In the present specification, the reverse transcription activity of reverse transcriptase can be measured by the following procedure. In this measurement method, when the enzyme activity is high, the sample containing the target to be measured may be appropriately diluted before measurement.
[0030] First, 10 μL of the following previously prepared solution A, 22 μL of solution B, 1 μL of solution C, and 12 μL of sterile water are added to a reaction vessel such as a microtube and mixed with stirring, then 5 μL of a sample solution containing the object to be measured or a diluted solution thereof is added and reacted at 42°C for 10 minutes. After cooling, 150 μL of the following solution D is added, stirred, and cooled on ice for another 10 minutes. This solution is filtered through a glass filter (Whatman GF / C filter), thoroughly washed with 0.1N hydrochloric acid and ethanol, and the radioactivity of the filter is measured using a liquid scintillation counter (Packard Tri-Carb2810 TR) to measure the incorporation of nucleotides. One unit of enzyme activity is the amount of enzyme that incorporates 1 nmole of nucleotide into the acid-insoluble fraction per 10 minutes under these conditions. (Reagent for measuring reverse transcriptase activity) Solution A: 250 mM Tris-HCl (pH 8.3), 375 mM potassium chloride, 15 mM magnesium chloride, 50 mM dithiothreitol, ·B solution: 1mg / mL polyA, 1pmol / μL dT20, 10mM dTTP, ·C liquid: [3H]-dTTP, Solution D: 0.07M sodium pyrophosphate, 0.7M trichloroacetic acid.
[0031] [Measurement of remaining reverse transcription activity] Each mutant reverse transcriptase to be measured is diluted to 100 U / μL with a storage buffer (50 mM Tris-HCl (pH 7.5), 300 mM KCl, 50% glycerol, 0.1 mM EDTA), and the reverse transcription activity value before storage is measured according to the procedure described in the method for measuring reverse transcription activity. Next, each mutant reverse transcriptase to be measured diluted in the storage buffer is stored under a predetermined storage condition (specifically, for example, in a 25°C incubator for 10 to 35 days when evaluating storage stability over time; for example, in a 45°C to 55°C incubator for 5 minutes when evaluating thermal stability). After a predetermined time has elapsed from the start of storage (specifically, for example, after 10 to 35 days when evaluating storage stability over time; for example, after 5 minutes when evaluating thermal stability), the reverse transcription activity value after storage is measured according to the procedure described in the method for measuring reverse transcription activity in the same manner as before storage. Next, the residual activity rate can be calculated by dividing the reverse transcription activity value after storage by the reverse transcription activity value before storage, as shown in the following formula I. Residual activity rate (%) = (reverse transcription activity value after storage / reverse transcription activity value before storage) × 100 (Equation I)
[0032] In a further embodiment, the present invention provides a polynucleotide encoding the mutant reverse transcriptase of the present invention as described above. Here, the polynucleotide encoding the mutant reverse transcriptase refers to a polynucleotide that, for example, when expressed by a conventional method, gives a protein of the mutant reverse transcriptase of the present invention. That is, it refers to a polynucleotide composed of a base sequence corresponding to the amino acid sequence of the protein of the mutant reverse transcriptase of the present invention. Those skilled in the art can easily determine the base sequence corresponding to a given amino acid sequence according to a codon table well known in the art. In addition, the polynucleotide encoding the mutant reverse transcriptase of the present invention also includes polynucleotides that differ due to codon degeneracy. The polynucleotide may be any nucleic acid polymer such as DNA or RNA.
[0033] In a further embodiment, the present invention provides a vector comprising the polynucleotide. Specifically, the polynucleotide encoding the mutant reverse transcriptase is transferred to a vector (e.g., an expression vector, a cloning vector, etc.) as necessary. The vector may be any vector that allows for the cloning and / or expression of the mutant reverse transcriptase of the present invention, and examples of such vectors include plasmids. Examples of plasmids include, but are not limited to, pUC118, pUC18, pBR322, pBluescript, pLED-M1, p73, pGW7, pET3a, and pET8c.
[0034] In a further embodiment, the present invention provides a cell transformed with the vector. Such a cell can be suitably used to express a protein encoding the mutant reverse transcriptase of the present invention. In a particular preferred embodiment, the recombinant host cell of the present invention is obtained by transforming a host cell with the expression vector. Examples of the host cell include Escherichia coli and yeast, and Escherichia coli is particularly preferred. Examples of Escherichia coli include Escherichia coli DH5α, JM109, HB101, XL1Blue, PR1, HS641(DE3), and BL21(DE3). That is, in the present invention, it is preferable to insert a gene encoding the mutant reverse transcriptase into the vector to make it an expression vector, and then transform a host cell with the expression vector.
[0035] In one embodiment, the expression vector of the present invention may contain elements that facilitate purification of the mutant reverse transcriptase, such as an extracellular secretion signal or a His tag.
[0036] In a further embodiment, a method for producing the mutant reverse transcriptase using the polynucleotide, the vector, the transformed cell, and / or a reagent containing one or more of them is also provided. For example, a host cell is transformed with the expression vector, and then spread on an agar medium containing a drug such as ampicillin to form a colony. The colony is inoculated into a nutrient medium, such as LB medium or 2×YT medium, and cultured at 37° C. for 12 to 20 hours, and then the cells are disrupted to extract a crude enzyme solution. Any known method may be used to disrupt the cells, and for example, a physical disruption method such as ultrasonic treatment, French press or glass bead disruption, or a lytic enzyme such as lysozyme may be used. Any method may be used to obtain a purified reverse transcriptase from the obtained crude enzyme solution, and for example, the mutant reverse transcriptase of the present invention can be isolated by subjecting the cells to centrifugation, ultracentrifugation, ultrafiltration, salting out, dialysis, ion exchange column chromatography, adsorption column chromatography, affinity chromatography, gel filtration column chromatography, or the like.
[0037] The present invention further provides a reverse transcription method characterized by using the mutant reverse transcriptase. The reverse transcription method of the present invention is characterized by synthesizing cDNA from an RNA template using the mutant reverse transcriptase of the present invention. The mutant reverse transcriptase of the present invention has higher thermal stability than the wild-type reverse transcriptase. Therefore, according to the reverse transcription method of the present invention, the reverse transcription reaction can be performed in a wide temperature range, including a temperature high enough to suppress the formation of secondary structures in RNA. Therefore, the reverse transcription method of the present invention can efficiently perform the reverse transcription reaction regardless of the type of RNA, and is highly versatile.
[0038] In one preferred embodiment, in the reverse transcription method of the present invention, the reverse transcription reaction can be carried out by incubating the mutant reverse transcriptase, a template RNA, an oligonucleotide primer complementary to a portion of the RNA, and four types of deoxyribonucleoside triphosphates in a reverse transcription reaction buffer.
[0039] The reaction temperature in the reverse transcription reaction varies depending on the type of RNA used, the type of mutant reverse transcriptase used, etc., and is therefore preferably set appropriately depending on the type of RNA used, the type of mutant reverse transcriptase used, etc. The reaction temperature can be set to 37 to 45°C, for example, when the RNA used is RNA that does not easily form a secondary structure. The reaction temperature can be set to a temperature higher than the reaction temperature suitable for wild-type reverse transcriptase, for example, 45 to 60°C, for example, when the RNA used is RNA that easily forms a secondary structure. The mutant reverse transcriptase of the present invention has high thermal stability, and therefore has the advantage that the reverse transcription reaction can be sufficiently carried out even under such high reaction temperature conditions. The reaction time can be, for example, about 1 minute to 1 hour, preferably about 5 minutes to 30 minutes, but is not limited thereto.
[0040] The reverse transcription buffer used in the reverse transcription method of the present invention may contain a divalent cation, such as a magnesium ion or a manganese ion. The concentration of the divalent cation is preferably set appropriately depending on the type of mutant reverse transcriptase and other components contained in the reverse transcription buffer. For example, the concentration of the divalent cation in the reverse transcription buffer is set to 1 to 30 mM. In addition, the reverse transcription buffer may contain components such as a reducing agent (e.g., dithiothreitol), a stabilizer (e.g., glycerol, trehalose), and an organic solvent (e.g., dimethyl sulfoxide, formamide), as necessary, within a range that does not impede the object of the present invention.
[0041] In a further embodiment, the present invention provides a reagent comprising the mutant reverse transcriptase, the polynucleotide, the vector, and / or the cell. These reagents may contain other optional components (e.g., optional additives such as stabilizers, preservatives, etc.) depending on the intended use, etc. For example, a reagent comprising the mutant reverse transcriptase may further comprise the reverse transcription reaction buffer, etc. The use of the reagent of the present invention is not particularly limited, and for example, it can be suitably used for a reverse transcription reaction in which cDNA is synthesized using RNA as a template. Furthermore, the reagent of the present invention can be suitably used for producing the mutant reverse transcriptase of the present invention.
[0042] In a further embodiment, the present invention provides a kit comprising the mutant reverse transcriptase, the polynucleotide, the vector, the cell, and / or a reagent containing one or more of these. The kit of the present invention may be, for example, a kit for performing a reverse transcription reaction to synthesize cDNA using RNA as a template, a kit for producing the mutant reverse transcriptase of the present invention, etc., but is preferably a kit used to synthesize cDNA using RNA as a template (also referred to as a reverse transcription reaction kit, etc.).
[0043] In one embodiment, the reverse transcription kit of the present invention is a kit for performing a reverse transcription reaction, and is characterized in that it contains the mutant reverse transcriptase of the present invention (including cases where it is provided as a reagent containing the mutant reverse transcriptase). Since the reverse transcription kit of the present invention contains the mutant reverse transcriptase of the present invention having high thermal stability, it can be suitably used even in reverse transcription reactions in a wide temperature range including a temperature high enough to suppress the formation of secondary structures in RNA. In addition, since it contains a reverse transcriptase with improved stability during storage, the management of the kit during transportation and storage is easier than before, and the kit can be suitable for long-term storage, making it highly convenient. The kit of the present invention may further contain instructions for use when performing a reverse transcription reaction using the mutant reverse transcriptase of the present invention. The kit of the present invention can be provided in an embodiment in which the mutant reverse transcriptase and the like are packaged in a single package, for example, and information on the method of using the kit is included.
[0044] In a specific embodiment, for example, in a reverse transcription reaction kit, the reagents required for carrying out the reverse transcription reaction may be sealed in a container different from the container containing the mutant reverse transcriptase, or may be sealed in the same container as the mutant reverse transcriptase if the progress of the reverse transcription reaction during storage of the reagent is stopped.The reagents may be sealed in a container in an amount suitable for carrying out the reverse transcription reaction.This makes it possible to easily handle the reagents, since it is not necessary to mix each reagent in an amount suitable for the reverse transcription reaction. EXAMPLES
[0045] The present invention will be described in more detail below with reference to examples, although the present invention is not limited to these examples.
[0046] Example 1 Construction of MMLV reverse transcriptase plasmid DNA (SEQ ID NO: 2) encoding Moloney murine leukemia virus reverse transcriptase was cloned into pET-23b(+) to create a plasmid (pMMLV) incorporating wild-type MMLV. The plasmid with the mutation was created using pMMLV as a template and the KOD-PLUS- Mutagenesis Kit (Toyobo) according to the instructions. The plasmid created and the primers used are shown in Table 1. The resulting plasmid was transformed into BL21-CodonPlus Competent Cells (Agilent Technologies) and used to prepare the enzyme.
[0047] [Table 1]
[0048] Example 2: Obtaining reverse transcriptase The culture of the bacterial cells obtained in Example 1 was carried out as follows. First, 80 mL of sterilized TB medium (Molecular cloning 2nd edition, pA2) containing 100 μg / mL ampicillin was dispensed into a 500 mL Sakaguchi flask. A plasmid transformant previously cultured in 3 mL of LB medium (1% bactotryptone, 0.5% yeast extract, 0.5% sodium chloride) containing 100 μg / mL ampicillin at 37° C. for 16 hours was inoculated into this medium and cultured under aeration at 30° C. for 16 hours. Then, IPTG (manufactured by Nacalai Tesque) was added to a final concentration of 1 mM, and cultured under aeration at 30° C. for another 4 hours. The cells were collected from the culture medium by centrifugation and suspended in 50 mL of disruption buffer (10 mM Tris-HCl (pH 7.5), 300 mM KCl, 5% glycerol), and then disrupted by sonication to obtain a cell lysate. The cell lysate was then purified using a His GraviTrap (GE Healthcare). The washing conditions were 10 mM Tris-HCl (pH 7.5), 300 mM KCl, 5% glycerol, and 50 mM imidazole, and the elution conditions were 10 mM Tris-HCl (pH 7.5), 300 mM KCl, 5% glycerol, and 300 mM imidazole. Finally, the buffer was replaced with a storage buffer (50 mM Tris-HCl (pH 7.5), 300 mM KCl, 50% glycerol, 0.1 mM EDTA) to obtain each mutant reverse transcriptase.
[0049] The activity of the purified reverse transcriptase was measured as follows. When the enzyme activity was high, the sample was diluted before measurement.
[0050] (Reagent for measuring reverse transcriptase activity) Solution A: 250 mM Tris-HCl (pH 8.3), 375 mM potassium chloride, 15 mM magnesium chloride, 50 mM dithiothreitol Solution B: 1mg / mL polyA, 1pmol / μL dT20, 10mM dTTP, Solution C: [3H]-dTTP D solution: 0.07M sodium pyrophosphate, 0.7M trichloroacetic acid
[0051] (Method for measuring reverse transcriptase activity) 10μL of solution A, 22μL of solution B, 1μL of solution C, and 12μL of sterile water were added to a microtube, stirred and mixed, and then 5μL of the purified enzyme dilution solution was added and reacted at 42℃ for 10 minutes. After cooling, 150μL of solution D was added, stirred, and then cooled on ice for another 10 minutes. This solution was filtered through a glass filter (Whatman GF / C filter), thoroughly washed with 0.1N hydrochloric acid and ethanol, and the radioactivity of the filter was measured using a liquid scintillation counter (Packard Tri-Carb2810 TR) to measure the incorporation of nucleotides. One unit of enzyme activity was defined as the amount of enzyme that incorporates 1 nmole of nucleotide into the acid-insoluble fraction per 10 minutes under these conditions.
[0052] As a result of the above measurements, it was confirmed that all of the modified MMLV reverse transcriptases of the present invention have sufficient reverse transcription activity comparable to that of the wild-type MMLV reverse transcriptase.
[0053] Example 3 Stability test of mutant reverse transcriptase Each mutant reverse transcriptase was diluted to 100 U / μL with storage buffer and stored in an incubator at 25° C. The reverse transcriptase activity of each mutant reverse transcriptase was measured 10, 25, and 35 days after the start of storage. The remaining activity rate was calculated by dividing the activity value after storage by the activity value before storage according to the following formula I. Residual activity rate (%) = (reverse transcription activity value after storage / reverse transcription activity value before storage) × 100 (Equation I)
[0054] [Table 2]
[0055] Table 2 shows the remaining activity rate of each mutant reverse transcriptase. Wild-type MMLV reverse transcriptase (WT) had low stability during storage at 25°C, with activity decreasing to 39% after 10 days and 8% after 35 days. On the other hand, each mutant reverse transcriptase in which the cysteine residue at the specified position shown in Table 2 was modified (substituted) with an alanine residue retained 45% or more of its activity after 10 days and 24% or more after 35 days. Among the mutant reverse transcriptases, C310A in particular contributed greatly to improving stability, and showed 50% remaining activity even after 35 days. It was shown that the reverse transcriptase of the present invention has improved stability during storage compared to the wild-type reverse transcriptase. The above results are for stability during storage at 25°C, but it is considered that stability is improved even under commonly used storage and transportation conditions such as 4°C and -20°C, and is very useful.
[0056] Example 4 Stability test of mutant reverse transcriptase 100U / μL of mutant reverse transcriptase (C310A) and wild-type reverse transcriptase (WT) prepared in the same manner as in Example 3 were stored in a 25°C incubator for 10 or 30 days. Each mutant reverse transcriptase was analyzed by non-reducing SDS-PAGE before and after storage. 200U of mutant reverse transcriptase was mixed with Sample Buffer (125mM Tris-HCl (pH 6.8), 4% (w / v) SDS, 20% glycerol, 0.01% BPB), incubated at 25°C for 1 hour, and then subjected to SDS-PAGE analysis. SuperSep Ace, 10% (Fujifilm Wako Pure Chemical Corporation) was used for SDS-PAGE analysis.
[0057] Figure 1 shows the results of non-reducing SDS-PAGE analysis of WT before storage (0 days) and after 30 days of storage (30 days), and Figure 2 shows the results of non-reducing SDS-PAGE analysis of C310A before storage (0 days) and after 30 days of storage (30 days). The analysis of WT confirmed that after incubation at 25°C for 30 days, the reverse transcriptase band (solid arrow in the figure) became weaker and the upper band of the reverse transcriptase (dotted arrow in the figure) became darker. This is due to the denaturation and inactivation of the reverse transcriptase during storage. On the other hand, the analysis of C310A mutant reverse transcriptase showed that the upper band (the band at the position corresponding to the dotted arrow in Figure 1) did not appear in the case of C310A mutant reverse transcriptase. This result also showed that C310A has improved stability during storage.
[0058] Example 5 Heat resistance test of mutant reverse transcriptase The mutant reverse transcriptases C90A, C157A, C236A, C262A, C409A, C495A, and C635A were diluted to 10 U / μL with a storage buffer (50 mM Tris-HCl (pH 7.5), 300 mM KCl, 50% glycerol, 0.1 mM EDTA) and heat-treated at 45°C for 5 minutes. Then, the reverse transcription activity was measured to determine the residual activity rate of each mutant reverse transcriptase after heat treatment. For the C310A mutant reverse transcriptase, in addition to the heat treatment at 45°C for 5 minutes, heat treatment at 50°C or 55°C for 5 minutes was also performed, and the residual activity rate was measured in the same manner. The residual activity rate was calculated by dividing the activity measurement result after heat treatment by the activity measurement result before heat treatment.
[0059] [Table 3] [Table 4]
[0060] As can be seen from Table 3, the WT had a residual activity rate of 65% after heat treatment at 45°C for 5 minutes, while each of the mutant reverse transcriptases showed a very high residual activity rate of about 80% to 95%. This indicates that each mutant reverse transcriptase has a significantly improved heat resistance. C310A, shown in Table 4, showed a residual activity of 93% after 45°C for 5 minutes, 70% after 50°C for 5 minutes, and 29% after 55°C for 5 minutes, indicating that its thermal stability is significantly improved compared to the WT. From the above, it can be seen that the thermal stability of each mutant reverse transcriptase is improved, and that C310A in particular made a particularly large contribution to the improvement of thermal stability.
[0061] Example 6 Heat resistance test of mutant reverse transcriptase (C310A, C310I, C310G) In the same manner as in Example 1, a mutant MMLV plasmid designed to modify the cysteine residue at position 310 to an isoleucine residue was prepared using pMMLV as a template and KOD-PLUS-Mutagenesis Kit (Toyobo). This plasmid was then transformed into BL21-CodonPlus Competent Cells (Agilent Technologies), which were cultured in the same manner as in Example 2 to prepare a mutant MMLV reverse transcriptase (C310I). The reverse transcriptase activity of the C310I mutant thus obtained was measured, and it was confirmed that it had sufficient reverse transcription activity comparable to that of the wild-type MMLV reverse transcriptase.
[0062] The C310A mutant prepared in Example 2 and the C310I mutant were diluted to 10 U / μL with a storage buffer (50 mM Tris-HCl (pH 7.5), 300 mM KCl, 50% glycerol, 0.1 mM EDTA) and heat-treated at 50° C. for 5 minutes. Thereafter, reverse transcription activity was measured, and the remaining activity rate after each heat treatment was calculated according to the above formula (I). As a comparative example, wild-type MMLV reverse transcriptase (WT) was also similarly heat-treated at 50° C. for 5 minutes, and the remaining activity rate after heat treatment was determined.
[0063] As a result, it was shown that the residual activity rate of the C310A mutant reverse transcriptase after heat treatment at 50°C for 5 minutes was about 1.19 times that of the wild-type MMLV reverse transcriptase (WT) as a comparison example, and that the C310I mutant reverse transcriptase was about 1.26 times that of the C310I mutant reverse transcriptase after heat treatment at 50°C for 5 minutes. From this result, it was confirmed that the stability of the reverse transcriptase was improved not only when the cysteine residue (C) at position 310 was modified to an alanine residue (A) but also when it was replaced with an isoleucine residue (I). It is known that alanine and isoleucine are both non-polar amino acids with an isoelectric point of about 6.0 and exhibit common properties. Therefore, it can be seen that particularly high stability can be obtained by modifying the cysteine residue in the MMLV reverse transcriptase to such an amino acid residue. Similarly, we prepared a new mutant MMLV reverse transcriptase (C310G) in which the cysteine residue at position 310 was modified to a glycine residue, and evaluated its stability under heat treatment at 50°C for 5 minutes.The mutant showed a higher residual activity than the wild-type MMLV reverse transcriptase, confirming improved stability. [Industrial Applicability]
[0064] The present invention provides a modified reverse transcriptase having excellent stability, which is useful in the field of molecular biology, and a reagent, a kit, etc., containing the reverse transcriptase. The present invention is particularly useful in gene expression analysis, and is highly versatile and convenient, and therefore can be used not only for research purposes but also for clinical diagnosis, environmental testing, etc.
Claims
1. A mutant reverse transcriptase having an amino acid sequence having 90% or more identity to the amino acid sequence set forth in SEQ ID NO: 1, in which a cysteine residue has been modified at at least one position selected from the group consisting of positions 90, 157, 236, 262, 310, 409, 495, and 635, wherein the modification of the cysteine residue is a substitution with at least one non-polar amino acid residue selected from the group consisting of alanine, glycine, valine, isoleucine, phenylalanine, proline, methionine, and tryptophan.
2. The mutant reverse transcriptase according to claim 1, wherein the modification of the cysteine residue is a substitution with at least one non-polar amino acid residue selected from the group consisting of alanine, glycine, valine, and isoleucine.
3. The mutant reverse transcriptase according to claim 1 or 2, wherein the modification of the cysteine residue is a substitution with an alanine residue.
4. A mutant reverse transcriptase described in any one of claims 1 to 3, characterized in that in an amino acid sequence having 90% or more identity to the amino acid sequence set forth in SEQ ID NO: 1, at least a cysteine residue at a position corresponding to position 310 has been modified.
5. The mutant reverse transcriptase according to claim 4, wherein the modification of the cysteine residue at the position corresponding to position 310 is a substitution with a non-polar amino acid residue selected from the group consisting of alanine, glycine, valine, and isoleucine.
6. The mutant reverse transcriptase according to claim 4 or 5, wherein the modification of the cysteine residue at the position corresponding to position 310 is a substitution with an alanine residue.
7. A mutant reverse transcriptase according to any one of claims 1 to 6, which lacks RNase activity.
8. The mutant reverse transcriptase according to any one of claims 1 to 7, which exhibits a residual activity rate of 30% or more when stored at 25°C for 35 days.
9. 9. The mutant reverse transcriptase according to claim 1, which exhibits a residual activity rate of 50% or more when stored at 25° C. for 35 days.
10. A polynucleotide encoding the mutant reverse transcriptase according to any one of claims 1 to 9.
11. A vector comprising the polynucleotide of claim 10.
12. A cell transformed with the vector of claim 11.
13. A reagent comprising at least one selected from the group consisting of the mutant reverse transcriptase according to any one of claims 1 to 9, the polynucleotide according to claim 10, the vector according to claim 11, and the cell according to claim 12.
14. A method for producing a mutant reverse transcriptase described in any one of claims 1 to 9 using at least one selected from the group consisting of a polynucleotide described in claim 10, a vector described in claim 11, a cell described in claim 12, and a reagent described in claim 13.
15. A method for reverse transcription, comprising synthesizing cDNA from an RNA template using the mutant reverse transcriptase according to any one of claims 1 to 9.
16. A kit comprising the mutant reverse transcriptase according to any one of claims 1 to 9.
17. The kit according to claim 16, which is used for synthesizing cDNA using RNA as a template.
Citation Information
Patent Citations
Angle detector
JP1986080002A
Variant type reverse transcriptase
JP2000139457A
MMLV reverse transcriptase variants
US20180312822A1
